Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AFNT-211 |
Trade Name | |
Synonyms | AFNT211|AFNT 211 |
Drug Descriptions |
AFNT-211 comprises autologous T-cells expressing a T-cell receptor targeting KRAS G12V in the context of HLA-A*11:010 and modified to enhance cell persistence, which potentially induces antitumor immune activity and cytotoxicity in KRAS G12V-expressing tumor cells (J Clin Oncol, 41, no. 16_suppl (2023) 2543). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AFNT-211 | AFNT-211 | 0 | 1 |